glp-1 drugs heart failure Stopping can quickly erase cardiovascular benefits – WashU Medicine Uncovering hidden opportunities in the

Grey-market semaglutide risks you need to understand The Amino Asylum shutdown is a case study, but the risks it illustrates apply to every grey-market semaglutide purchase

An injection is a medical procedure, and what youre putting into your body has to be the right stuff, at the right dose

Horowitz, R

In clinical trials, tirzepatide helped patients lose an average of 20.9% of their body weight over 72 weeks

Genome-wide analysis of human long noncoding RNAs: a provocative review

Preclinical data suggest that the most pronounced weight loss occurs when GCGR potency exceeds that of GLP1R or GIPR, supporting the concept of triple agonism as a promising therapeutic approach for obesity 9,27